Demographics | Â |
 n | 27 |
 Median age (IQR), years | 40 (26–54) |
 < 18 years | 23% (4/27) |
 Male sex | 55% (15/27) |
 Days from symptom onset to admission (median, IQR), n = 24 | 3.5 (2–7) |
Clinical presentation | |
 Encephalitis | 93% (25/27) |
 Stroke-like | 4% (1/27) |
 Unspecific | 4% (1/27) |
Diagnostic testing | |
 HSV-1 (PCR of CSF) | 59% (16/27) |
 HSV-2 (PCR of CSF) | 7% (2/27) |
 HSV not distinguished (PCR of CSF) | 26% (7/27) |
 HSV not distinguished (antibody of CSF) | 4% (1/27) |
 PCR negative for HSV (CSF) | 4% (1/27) |
CSF findings | |
 Pleocytosis (> 4 cells/μl) | 88% (21/24) |
 Median cell count#(cells/μl, IQR, n = 23) | 88 (25–387) |
Neuroimaging | |
 Hemorrhage on first imaging | 32% (8/25) |
 Hemorrhage after admission | 68% (17/25) |
 Days from admission to detection of hemorrhage (median, IQR) | 10 (9–14) |
 Hemorrhage within HSE predilection sites | 89% (24/27) |
 Bilateral temporal lobe HSE | 33% (8/24) |
 Atypical localization of hemorrhage | 7% (2/27) |
 No encephalitic lesion | 4% (1/27) |
 Evidence for vasculitis | 0% (0/9) |
Intervention | |
 Hematoma evacuation | 30% (8/27) |
Outcome | |
 Good outcome (mRS 0–2) | 38% (8/24) |
 Unfavorable outcome (mRS 3–5) | 41% (11/24) |
 Fatality | 21% (5/24) |